A Therapeutic Confirmatory Study of Epaminurad Versus Febuxostat in Gout Patients

NCT05815901 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

612

Enrollment

INDUSTRY

Sponsor class

Conditions

Gout

Interventions

DRUG: Epaminurad 6 mg
DRUG: Epaminurad 9 mg
DRUG: Febuxostat 40 mg
DRUG: Febuxostat 80 mg
DRUG: Epaminurad 6 mg placebo
DRUG: Epaminurad 9 mg placebo
DRUG: Febuxostat 40 mg placebo
DRUG: Febuxostat 80 mg placebo

Sponsor

JW Pharmaceutical